Perception of non-alcoholic fatty liver disease: Real-life experience from Pakistan by Butt, Nazish et al.
eCommons@AKU 
Section of Gastroenterology Department of Medicine 
6-29-2021 
Perception of non-alcoholic fatty liver disease: Real-life 
experience from Pakistan 
Nazish Butt 
Muhammad Ali Khan 
Lajpat Rai 
Riaz Hussain Channa 
Hanisha Khemani 
See next page for additional authors 
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_med_gastroenterol 
 Part of the Digestive System Diseases Commons, and the Gastroenterology Commons 
Authors 
Nazish Butt, Muhammad Ali Khan, Lajpat Rai, Riaz Hussain Channa, Hanisha Khemani, and Amanullah 
Abbasi 
Review began  06/16/2021 
Review ended  06/17/2021 
Published 06/29/2021
© Copyright 2021
Butt et al. This is an open access article
distributed under the terms of the
Creative Commons Attribution License
CC-BY 4.0., which permits unrestricted
use, distribution, and reproduction in any
medium, provided the original author and
source are credited.
Perception of Non-Alcoholic Fatty Liver Disease:
Real-Life Experience From Pakistan
Nazish Butt    , Muhammad Ali Khan  , Lajpat Rai  , Riaz Hussain Channa  , Hanisha Khemani  ,
Amanullah Abbasi 
1. Gastroenterology, National Medical Centre, Karachi, PAK 2. Gastroenterology, Aga Khan University Hospital,
Karachi, PAK 3. Gastroenterology, Jinnah Postgraduate Medical Centre, Karachi, PAK 4. Internal Medicine, Jinnah
Postgraduate Medical Centre, Karachi, PAK 5. Gastroentrology, Jinnah Postgraduate Medical Centre, Karachi, PAK 6.
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
Corresponding author: Muhammad Ali Khan, aleekhan3333@gmail.com
Abstract
Introduction
Non-alcoholic fatty liver disease (NALFD) has become one of the most pervasive causes of hepatic
pathology. Because of its marked association with metabolic syndrome, type II diabetes and cardiovascular
disease, NAFLD has gained substantial focus recently. Its prevalence and incidence are on the rise in
Pakistan. However, due to its indolent and mostly asymptomatic course, NAFLD is often overlooked. This
reckless behavior towards a potentially deadly disease is influenced most notably by disinformation or
flawed perception, although there are a number of other complex socioeconomic components to this as well.
With respect to NAFLD, the gap between disease understanding and steps for management is growing in the
Pakistani society. With this study, we hoped and aimed to evaluate just how far and wide these
shortcomings were found and how was NAFLD perceived in the local populace via a self-administered
survey.
Methods
This was a cross-sectional observational cohort study undertaken at the Department of Gastroenterology,
Jinnah Postgraduate Medical Centre, and Medical Unit II, Dow University of Health Sciences, Ojha Campus,
Karachi, Pakistan. All patients ≥18 years with a diagnosis of NAFLD were included in the study. NAFLD was
diagnosed on the basis of sonographic evidence. All ultrasounds were done by a senior expert radiologist
with at least 10 years of postgraduate experience. Ultrasounds were performed twice in all patients to rule
out human error and bias. Perceptions regarding the knowledge of NAFLD were assessed using a self-
administered survey questionnaire.
Results
The female-to-male ratio in our cohort was 3:1. The mean age and body mass index (BMI) recorded were
39.85 ± 9.79 years and 31.21 ± 3.6 kg/m2, respectively. Sixty participants (26.4%) knew about their disease
(NAFLD) while only 36 (15.9%) knew what NAFLD was and only 33 (14.5%) participants knew about the
cardiovascular risk associated with it. Nearly two-thirds of the patients considered themselves overweight,
while 180 (79.3%) of them were willing to lose weight. However, just about half of the cohort admitted the
need for improved eating habits and increased physical activity/exercise in their daily lives. Fifty-seven
(25.1%) patients admitted to using alternative or quack medications and only 45 (19.8%) patients considered
them harmful.
Conclusions
Patients harboring NAFLD have little to no knowledge about the disease and its nature or the fact that they
are suffering from it despite being diagnosed clinically. Furthermore, while the general populace is willing to
accept being overweight and having unhealthy eating habits, their willingness in initiating real-life practical
steps to manage NAFLD is lacking.
Categories: Gastroenterology
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Introduction
Ludwig et al. first described an unnamed liver disease in 1980 that imitated alcoholic hepatitis and could
lead to cirrhosis [1]. This disease was characterized by the accumulation of abnormal levels of fat within the
hepatic parenchyma, evident by radiological or histological examination and occurring in the absence of
other causes of liver injury, such as alcoholism, chronic hepatitis, inherited metabolic liver disorders, and
drugs. Further examination of biopsy specimens revealed lobular hepatitis, focal necrosis with mixed
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inflammatory infiltrates, Mallory bodies, and even cirrhosis. This non-alcoholic hepatic disorder would
eventually be known as non-alcoholic fatty liver disease (NAFLD) [2].
In the few decades since its first report, NALFD has become one of the most pervasive causes of hepatic
pathology. With the currently declining incidence of chronic viral hepatitis and a burgeoning obesity
epidemic, NAFLD will become the leading cause of liver disease universally sooner than later [3]. The
approximate prevalence of NAFLD worldwide is 25%, putting the burden of this disease at an astonishing 1.7
billion patients [4]. Higher prevalence rates have been recorded in the Middle Eastern nations and the USA,
whereas much lower prevalence rates are reported from Africa [4]. Nonetheless, NAFLD is now becoming
endemic in every nation and continent on the planet and accounts for a major share of healthcare costs with
each passing year [5].
Perception is reality. The general populace can only be expected to follow protocols, implement healthy
nutritional regimens, make necessary adjustments to their daily routines, avoid precipitating factors, and
adapt to the changing dynamics of a disease if they perceive that disease to be a threat to their own well-
being [6-9]. The current coronavirus disease 2019 (COVID-19) pandemic has made clear the counterintuitive
impact of redundant and unscientific attitudes or beliefs in imposing necessary standard operating
procedures and vaccination drives for controlling a devastating disease [10,11]. Most, if not all, of these
misplaced notions are due to misapprehensions about the disease, its pathophysiology, and eventual
outcomes [12,13]. Incorrect perceptions about a disease can lead to irresponsible behaviors, with
detrimental actions. For example, in the case of COVID-19, misguided perceptions have led to a calamitous
situation in some regions of the world. However, this can occur with any disease process anytime and
anywhere, and NAFLD is no exception.
Due to the indolent nature of NAFLD and its largely asymptomatic presentation, patients often misinterpret
or misperceive the danger it represents overtime. NAFLD is closely linked to metabolic syndrome (metS) and
type II diabetes mellitus [14,15]. Consequently, over half of the mortality in patients with NAFLD occurs
because of adverse cardiovascular events [16,17]. The next two major causes of NAFLD morbidity and
mortality are cirrhosis and the development of hepatocellular carcinoma (HCC) [18]. These grave outcomes
highlight the need for a proper understanding of the disease on the patient’s side and place an equal onus
on the physician to recognize the need for monitoring and intervention in patients with NAFLD [19].
Previous studies that have evaluated the perception of NALFD in the general populace have demonstrated
an overall indifferent attitude toward the disease, as the participants were either uneducated about the
disease or did not consider themselves at risk [20,21]. Other reports exposed clear-cut communication gaps
between the patients and physicians with regard to NALFD, as most doctors did not discuss the disease
adequately with their subjects and the patients themselves seldom inquired about the disease they were
harboring [22]. Most data on patient perceptions of NAFLD are derived from studies conducted in developed
nations with high literacy rates, easy access to information, and standardized healthcare systems. A safe
assumption is that the same shortcomings would be encountered in the developing world, only more
pronounced. In the present study, we surveyed the factors that shape the perception of NAFLD in the
Pakistani populace.
Materials And Methods
This cross-sectional observational cohort study was conducted from January 2017 to December 2020 (four
years) at the Department of Gastroenterology, Jinnah Postgraduate Medical Centre (JPMC), and Medical Unit
II, Dow University of Health Sciences, Ojha Campus, Karachi, Pakistan. Patients aged 18 years or older of
either gender who were diagnosed with NAFLD were included in the study. NAFLD was diagnosed via
ultrasound carried out twice in all patients to reduce human error and bias. All ultrasound/sonographic
examinations were carried out by a member of the team of senior radiologists at either institute, all of whom
have postgraduate qualifications and at least 10 years of experience. The spectrum of NAFLD consists of two
entities: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). However, for the
purposes of this study, we did not distinguish between the two and simply enrolled all patients with fatty
infiltration evident on ultrasound. Body mass index (BMI) was calculated by dividing the weight of the
patient in kilograms by the height in meters squared.
Patients with chronic viral hepatitis, alcoholic hepatitis, compensated liver disease, renal failure, heart
failure, thyroid and parathyroid disorders, terminal illnesses, and metastatic malignancy were all excluded
from the study. All biochemical and radiological workups to rule out concomitant diseases were done free of
cost to the patients. The institutional review board of JPMC gave approval for this research beforehand.
Written consent was obtained in all cases, and patient confidentiality was ensured at all times. Participants
were required to fill out a simple questionnaire designed to record the baseline patient characteristics and
their perceptions of NAFLD (Table 1). The 12 questions were designed to focus on the main aspects of the
disease that may impact eventual outcomes, including knowledge of having the disease and its association
with adverse cardiovascular events, the weight of the patients and their physical activity/exercise, dietary
habits, and use of quack medications. Questionnaires were always completed in the outpatient department
(OPD) in the presence of an attendant. A resident or senior registrar was readily available to address any
queries regarding the questionnaire.
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Please answer the questions as only “Yes” or “No”
Do you know what disease you have? Yes No
Do you know what fatty liver is? Yes No
Do you know NAFLD is associated with CVDs? Yes No
Do you think you are overweight? Yes No
Has anyone told you that you are overweight? Yes No
Do you think you need to lose weight? Yes No
Do you think you overeat? Yes No
Do you think you eat inappropriate food? Yes No
Do you think you get enough exercise? Yes No
Do you think the chores of the house is exercise? Yes No
Have you ever taken Hakeemi medication? Yes No
Do you consider Hakeemi medications harmful? Yes No
TABLE 1: Questionnaire assessing the perception of NAFLD
NAFLD = non-alcoholic fatty liver disease; CVD = cardiovascular disease
Data were entered and analysed using the Statistical Package for the Social Sciences (SPSS) for Windows,
Version 21.0 (IBM Corp., Armonk, NY). A consecutive and non-probability sampling technique was used for
this cohort. Means and standard deviations were calculated for the quantitative variables of age and BMI.
Frequencies and percentages were computed for the qualitative variables of gender, marital status, residence
(urban or rural), and socioeconomic status, and for the responses of either “Yes” or “No” in the
questionnaire.
Results
In total, 227 patients were enrolled in the study. The female-to-male ratio in our cohort was 3:1. The mean
age and BMI were 39.85 ± 9.79 years and 31.21 ± 3.6 kg/m2, respectively. As expected, a majority of the
patients were married and middle aged. The patients were predominantly from urban areas and belonged to
the low-income socioeconomic group. The general characteristics of the patients included in the study are
summarized in Table 2.
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Socioeconomic status  
Lower class 153 (67.4%)
Middle class 74 (32.59%)
Body mass index (kg/m2) 31.21 ± 3.6
TABLE 2: General characteristics of the patients enrolled in the study
Only 60 (26.4%) patients knew they had NAFLD, and even fewer knew the exact nature of their disease. Most
concerning, only 33 (14.5%) of the patients had some idea about the adverse cardiovascular events
associated with NAFLD. However, the vast majority of the patients recognized the need for better weight
control and admitted to their unhealthy eating habits. Despite this, only 74 (32.6%) recognized the need for
more physical activity/exercise in their daily lives. Only a small percentage of the patients had used quack
medications; however, most did not view these medications as harmful (see Discussion). The results of the
survey are shown in Table 3.
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Questions N=227
 Yes (%) No (%)
Do you know what disease you have? 60 (26.4%) 167 (73.6%)
Do you know what NAFLD is? 36 (15.9%) 191 (84.1%)
Do you know NAFLD is associated with CVDs? 33 (14.5%) 194 (85.5%)
Do you think you are overweight? 143 (63.0%) 84 (37.0%)
Has anyone told you that you are overweight? 158 (69.6%) 69 (30.4%)
Do you think you need to lose weight? 180 (79.3%) 47 (20.7%)
Do you think you overeat? 153 (67.4%) 74 (32.6%)
Do you think you eat inappropriate food? 126 (55.5%) 101 (44.5%)
Do you think you get enough exercise? 114 (50.2%) 113 (49.8%)
Do you think the chores of the house is exercise? 98 (43.2%) 129 (56.8%)
Have you ever taken Hakeemi medication? 57 (25.1%) 170 (74.9%)
Do you consider Hakeemi medications harmful? 45 (19.8%) 180 (80.2%)
TABLE 3: Results of the survey on the perception of NAFLD
NAFLD = non-alcoholic fatty liver disease; CVD = cardiovascular disease
Discussion
Nearly 70% of all patients enrolled in the study were from urban centers; this is simply a representation of
the diverse group of people treated at JPMC on a daily basis. All reports from urban centers about metS, type
II diabetes mellitus, and NAFLD have previously illustrated a disproportionately raised prevalence and
incidence rates among women [23]. However, the differences between the rates for men and women for all
three entities were comparable and only became apparent in later age groups (i.e., 40 years or above) [24].
Three-quarters of our participants were female, but the higher incidence of NAFLD in women cannot explain
this observation to this degree. Our opinion is that this matter reflects complex social circumstances and is
therefore beyond the scope of this cohort. The mean age recorded in our study was 39.85 ± 9.79 years; this
relatively young age is consistent with the obesity pandemic that is now affecting an ever younger populace
and is being reported universally [4,14,23,24].
Providing objective parameters regarding a person’s socioeconomic status is nearly impossible in today’s
volatile economic environment. Therefore, we did not define economic status per se; instead, this choice was
made by the patients themselves. Traditionally, NAFLD has been associated with a high income and the
lifestyle that accompanies it, but our results do not concur with this association [25]. Our observations verify
that NAFLD has evolved over the years and is no longer affected by the economic status of the patients. Even
in the most impoverished societies, a sedentary lifestyle and the obesity pandemic seem to have taken hold
(this is more evident in Pakistani rural societies, where daily wages are as low as 1 USD per day). Moreover,
as with other aspects of NAFLD, this phenomenon is now being observed and reported more frequently
[4,26].
We surveyed five distinct aspects of NAFLD. Questions 1-3 asked whether the patients knew they were
harboring NAFLD. The follow-up questions determined whether the patients actually knew or even had the
slightest idea of what NAFLD was and what it entailed for their cardiovascular risk. Only one in four patients
knew about being diagnosed with NAFLD, only half of those patients knew what NAFLD was, and even fewer
were aware of their increased cardiovascular risk due to NAFLD. Overall, only one in nine patients was fully
aware of one's disease. Several previous authors have mentioned the indifferent attitudes patients have
toward NAFLD [20-22]. Nevertheless, the massive gap observed in our study between disease prevalence and
the lack of NAFLD knowledge has not been reported in the current literature. To the best of our knowledge,
this is the first study on the perception of NAFLD in Pakistan. Any comparison of data between developed
and underdeveloped parts of the world is difficult due to the huge differences in standards of living and
healthcare systems; however, with our evidence, we can safely assume that the pitfalls seen with respect to
NAFLD and its perception in developed nations are further widened in states like Pakistan.
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Obesity, unlike NAFLD, is easily observed even by a third party. Questions 4-6 analysed the perception of
body weight among our participants. A mean BMI of 31.21 ± 3.6 kg/m2 verified that obesity was rampant
among our subjects. Weight loss and, by extension, healthy eating/nutrition are the gold standards for
managing NAFLD [27,28]. For this reason, the observation that 8 in 10 patients recognized the need for
weight loss was heartening. Still, a small proportion did not accept being overweight, and those patients
required extensive counseling. A high number of patients were willing to undergo weight-loss programs, but
most did not admit to their unhealthy eating habits. About half admitted to frequent overeating, and
approximately 44% admitted to eating unhealthy foods. Similar positions were seen pertaining to the need
for more exercise/physical activity.
This denial of unhealthy eating habits and the lack of physical activity represent the greatest, but most
amenable, hurdle in tackling the epidemic of NAFLD. Counseling through doctors, specialists, and dieticians
can play an important role in reaching this goal, but systemic changes must be instituted to curb the disease.
Encouraging exercise, providing healthier alternatives to fast foods and energy drinks, educating the youth,
promoting sports, and convening advertising campaigns on the consumption of more fresh fruits and
vegetables are just a few strategies that can be employed on a large scale to avert a healthcare disaster.
We also independently evaluated one factor that affects liver pathology, namely, “Hakeemi” medications.
These are quack medications that are neither registered nor regulated by any authority but are regularly used
in Pakistani society [29]. The constituents of these “drugs” are not known, side effects are not recorded, and
dosages are not set. They can be administered by virtually anyone via any route, do not have labels, can be
used (falsely) for any and all ailments, have no preparation details, and can be prescribed through word of
mouth only (i.e., no written prescription), with no evidence of the transactions between the patients and
quacks. These medications are also notorious for causing renal dysfunction [30]. Liver damage has been
reported, but no definitive data are available locally, and only expert opinions or recommendations exist.
Similarly, “Hakeemi” preparations have been reported to cause fatty liver, but again no definitive proof
exists, for the reasons discussed above. The main point we wanted to highlight in the present study was just
how comfortable the general populace is with the use of these deleterious substances. Only a quarter of the
patients had previously used “Hakeemi” substances, yet more than 80% did not consider them harmful. This
represents considerable confidence in products with such extreme shortcomings without any experience
with them. The use of these substances represents a longstanding problem in the region, but it has been
difficult to control. Since no drugs are specifically approved for NAFLD, quacks can lure patients with false
promises of disease resolution, and this has been seen to cause further deterioration in other illnesses [30].
Limitations of the study
We did not differentiate between the different stages of NAFLD (or NASH) via biopsy or histopathology.
Educational status was not included in the study to recruit a wider array of participants; however, this could
have led to human bias and lack of understanding in some patients.
Conclusions
Patients with NAFLD have little knowledge about the disease they harbor, its nature, its implications, and
the need for intervention. This represents a major gap between disease causality and its understanding and
eventual outcomes that can only be bridged by introducing policy in the form of clinical guidelines,
awareness campaigns, civil society involvement, and healthcare system reforms including registries. For the
moment, further exploration of the awareness of and attitudes towards NAFLD is needed to develop
effective strategies for combating this disease in Pakistan.
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